Welcome to our dedicated page for Marinus Pharmace news (Ticker: MRNS), a resource for investors and traders seeking the latest updates and insights on Marinus Pharmace stock.
Marinus Pharmaceuticals (MRNS) is a clinical-stage biopharma company advancing ganaxolone for rare neurological disorders, including epilepsy and CDKL5 deficiency disorder. This page aggregates official announcements and verified updates about the company's therapeutic developments and regulatory progress.
Investors and researchers will find timely updates on clinical trial outcomes, FDA designations, and strategic partnerships. Our curated collection ensures access to primary source materials including press releases, regulatory filings, and milestone achievements.
Key content includes updates on ganaxolone's development pathway, orphan drug status details, and analyses of the company's position in neurotherapeutics. All materials are sourced directly from company communications to ensure accuracy.
Bookmark this page for streamlined tracking of MRNS's progress in addressing high-need neurological conditions through innovative therapeutic development.
Marinus Pharmaceuticals (Nasdaq: MRNS) announced an underwritten public offering of its common stock, with all shares offered by the company. The underwriters have a 30-day option to purchase an additional 15% of the offering. Cantor Fitzgerald & Co. is the sole bookrunner. Proceeds will fund product development and general corporate needs, including capital expenditures and clinical trials. The offering will utilize a shelf registration statement effective since July 27, 2020. This press release does not constitute an offer to sell or solicit an offer to buy securities.
Marinus Pharmaceuticals (Nasdaq: MRNS) announced a virtual Scientific Exhibit at the American Epilepsy Society Annual Meeting, featuring 10 posters on clinical programs for CDKL5 deficiency disorder (CDD) and refractory status epilepticus (RSE). Key highlights include latest analyses from the Phase 3 Marigold Study showing significant reductions in seizure frequency with ganaxolone across various patient subgroups. The company is also launching an expanded access program for CDD patients and plans to meet with the FDA in Q1 2021 regarding NDA submissions.
Marinus Pharmaceuticals (Nasdaq: MRNS) hosted a virtual Scientific Exhibit at the American Epilepsy Society Annual Meeting, featuring 10 posters on its clinical development programs for CDKL5 deficiency disorder (CDD) and refractory status epilepticus (RSE). Key highlights included data from the Phase 3 Marigold Study, demonstrating significant seizure reduction in CDD patients treated with ganaxolone, with a median reduction of 52.7% over 12 months. The company plans to meet with the FDA in Q1 2021 regarding its NDA submission for CDD and has launched an expanded access program for ganaxolone.
Marinus Pharmaceuticals (MRNS) has launched an expanded access program (EAP) to provide ganaxolone to patients with CDKL5 Deficiency Disorder (CDD) who did not participate in the Phase 3 Marigold Study. The decision comes after the trial demonstrated a significant 32.2% reduction in major motor seizures compared to 4.0% for placebo. Marinus plans to submit a new drug application to the FDA in mid-2021. The EAP is initially available in the US, targeting patients aged two and older suffering from uncontrollable seizures.
Marinus Pharmaceuticals, Inc. (MRNS) announced the grant of inducement awards to two new employees, comprising non-qualified stock options for 10,000 shares. The exercise price is set at $14.54 per share, matching the closing price on December 3, 2020. These options will vest 25% on the one-year anniversary of employment and the remaining 75% in monthly installments over three years, contingent on ongoing employment. Marinus focuses on innovative treatments for rare seizure disorders, with its lead product, ganaxolone, undergoing multiple clinical trials.
Marinus Pharmaceuticals (Nasdaq: MRNS) will host a webinar on December 7, from 12:00 PM to 2:00 PM ET, providing a clinical update on its pipeline addressing rare seizure disorders. Key topics include Status Epilepticus, CDKL5 Deficiency Disorder, and Tuberous Sclerosis Complex. The event features expert presentations, including insights from Dr. Elia M. Pestana Knight, and discussions on caregiver experiences and commercial strategy. This initiative aims to enhance understanding of Marinus’ therapies and pipeline.
Marinus Pharmaceuticals (MRNS) announced the selection of four abstracts focusing on clinical trial data for ganaxolone at the American Epilepsy Society Annual Meeting (AES2020), occurring from December 4-8, 2020. Highlights include results from the pivotal Marigold Phase 3 study in CDKL5 deficiency disorder and the use of ganaxolone in refractory status epilepticus. Additionally, six other posters related to Marinus will be presented during a virtual Scientific Exhibit on December 7, showcasing the drug's extensive therapeutic potential.
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) announces the grant of 134,000 stock options to two new employees as inducement for their employment. The options, priced at $13.71 per share, will vest 25% on the one-year anniversary of employment and the remainder in 36 monthly installments, contingent on continued employment. Marinus focuses on developing innovative therapies for rare seizure disorders, with its lead candidate, Ganaxolone, undergoing multiple clinical trials.
Marinus Pharmaceuticals (Nasdaq: MRNS) reported its Q3 2020 results, highlighting significant milestones in its clinical programs. Notably, the Phase 3 Marigold Study demonstrated a 32.2% median reduction in major motor seizures in patients with CDKL5 Deficiency Disorder (CDD) using ganaxolone. The company has secured a cost-sharing contract with BARDA for its refractory status epilepticus program. Financially, Marinus reported a net loss of $15.7 million for Q3, with cash reserves of $91.3 million, sufficient to fund operations into 2022. NDA submission for CDD is anticipated in mid-2021.
Marinus Pharmaceuticals (MRNS) has appointed Christy Shafer as Chief Commercial Officer. Reporting to CEO Scott Braunstein, Shafer brings two decades of experience in biotech and pharmaceuticals, with expertise in neurology and commercial strategy. Her leadership is expected to enhance the commercial launch of ganaxolone, particularly for CDKL5 deficiency disorder. The company recently completed a pivotal Phase 3 trial for ganaxolone and is focused on expanding its clinical trials in related conditions. This strategic hire is aimed at driving growth and maximizing the drug's market potential.
FAQ
What is the current stock price of Marinus Pharmace (MRNS)?
What is the market cap of Marinus Pharmace (MRNS)?
